Ellagic acid-imbedded MoO(3) nanowires architecture: External mediator-less electrochemical immunoprobing of inflammatory bowel disease marker
Abstract
Oxidative stress biomarkers such as 8-iso-prostaglandin F(2alpha) (8-iso-PGF2alpha) dictate a central dogma of clinically prevalent (non) communicable diseases such as inflammatory bowel disease (IBD) but are less explored owing to the complexity, sensitivity, and selectivity of conventional detecting methods. Thus, there is an urgent need for a rapid, simple, and reliable method for point-of-care (POC) detection of 8-iso-PGF2alpha. Herein, linker chemistry mediated ellagic acid imbedded MoO(3) NWs architecture is employed as an external mediator-free transducer to develop an 8-iso-PGF2alpha biosensor. The optimized biosensor provided robust and discriminative analytical performance for a wide range (0.5-5000 pg/mL) and LOD approximately 0.28 pg/mL with good reproducibility (RSD 2.0 %). The 8-iso-PGF2alpha biosensor's practicality towards clinical sample detection collected from IBD patients is demonstrated and cross-validated against the ELISA using the Blend-Altman technique, establishing a strong correlation, negligible bias and coefficient of variance (X = 6.88 %) with the added advantage of user-friendliness and fast analytical response ( approximately 60 s). Thus, the proposed biosensor is a reliable POC screening tool capable of predicting disease onset, monitoring progression, and assessing treatment efficacy in large longitudinal cohorts and clinical landscapes.